Will Stem Cell Profits Measure Up?: NxR Biotechnologies’ Alain Vertès – Seeking Alpha (registration)
|
Will Stem Cell Profits Measure Up?: NxR Biotechnologies' Alain Vertès
Seeking Alpha (registration) The market is still not valuing stem cell programs and companies fairly; this is a very exciting time for proposed stem cell therapies. Hopefully, with the accelerated pathway we're seeing in Japan, novel therapeutics will take a lot less time to get … |
